Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Genes Dev ; 30(9): 1101-15, 2016 05 01.
Article in English | MEDLINE | ID: mdl-27125671

ABSTRACT

An open and decondensed chromatin organization is a defining property of pluripotency. Several epigenetic regulators have been implicated in maintaining an open chromatin organization, but how these processes are connected to the pluripotency network is unknown. Here, we identified a new role for the transcription factor NANOG as a key regulator connecting the pluripotency network with constitutive heterochromatin organization in mouse embryonic stem cells. Deletion of Nanog leads to chromatin compaction and the remodeling of heterochromatin domains. Forced expression of NANOG in epiblast stem cells is sufficient to decompact chromatin. NANOG associates with satellite repeats within heterochromatin domains, contributing to an architecture characterized by highly dispersed chromatin fibers, low levels of H3K9me3, and high major satellite transcription, and the strong transactivation domain of NANOG is required for this organization. The heterochromatin-associated protein SALL1 is a direct cofactor for NANOG, and loss of Sall1 recapitulates the Nanog-null phenotype, but the loss of Sall1 can be circumvented through direct recruitment of the NANOG transactivation domain to major satellites. These results establish a direct connection between the pluripotency network and chromatin organization and emphasize that maintaining an open heterochromatin architecture is a highly regulated process in embryonic stem cells.


Subject(s)
Heterochromatin/genetics , Heterochromatin/metabolism , Mouse Embryonic Stem Cells/physiology , Nanog Homeobox Protein/metabolism , Animals , Cell Line , Chromatin/metabolism , Chromatin Assembly and Disassembly/genetics , Down-Regulation , Gene Deletion , Mice , Nanog Homeobox Protein/genetics , Protein Domains , Transcription Factors/genetics , Transcription Factors/metabolism
2.
Arch Immunol Ther Exp (Warsz) ; 63(2): 101-8, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25467949

ABSTRACT

Fully human antibodies from transgenic animals account for an increasing number of new therapeutics. After immunization, diverse human monoclonal antibodies of high affinity can be obtained from transgenic rodents, while large animals, such as transchromosomic cattle, have produced respectable amounts of specific human immunoglobulin (Ig) in serum. Several strategies to derive animals expressing human antibody repertoires have been successful. In rodents, gene loci on bacterial artificial chromosomes or yeast artificial chromosomes were integrated by oocyte microinjection or transfection of embryonic stem (ES) cells, while ruminants were derived from manipulated fibroblasts with integrated human chromosome fragments or human artificial chromosomes. In all strains, the endogenous Ig loci have been silenced by gene targeting, either in ES or fibroblast cells, or by zinc finger technology via DNA microinjection; this was essential for optimal production. However, comparisons showed that fully human antibodies were not as efficiently produced as wild-type Ig. This suboptimal performance, with respect to immune response and antibody yield, was attributed to imperfect interaction of the human constant region with endogenous signaling components such as the Igα/ß in mouse, rat or cattle. Significant improvements were obtained when the human V-region genes were linked to the endogenous CH-region, either on large constructs or, separately, by site-specific integration, which could also silence the endogenous Ig locus by gene replacement or inversion. In animals with knocked-out endogenous Ig loci and integrated large IgH loci, containing many human Vs, all D and all J segments linked to endogenous C genes, highly diverse human antibody production similar to normal animals was obtained.


Subject(s)
Antibodies, Monoclonal, Humanized/metabolism , Antibodies, Monoclonal/metabolism , Fibroblasts/physiology , Immunotherapy , Oocytes/physiology , Animals , Animals, Genetically Modified , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal, Humanized/genetics , Cattle , Humans , Immunoglobulin Constant Regions/genetics , Mice , Microinjections , Protein Engineering , Rats , Species Specificity
3.
BMC Biochem ; 13: 19, 2012 Oct 02.
Article in English | MEDLINE | ID: mdl-23031230

ABSTRACT

BACKGROUNDS: Streptococcus pneumoniae expresses three distinct sialidases, NanA, NanB, and NanC, that are believed to be key virulence factors and thus, potential important drug targets. We previously reported that the three enzymes release different products from sialosides, but could share a common catalytic mechanism before the final step of product formation. However, the kinetic investigations of the three sialidases have not been systematically done thus far, due to the lack of an easy and steady measurement of sialidase reaction rate. RESULTS: In this work, we present further kinetic characterization of pneumococcal sialidases by using a direct spectrophotometric method with the chromogenic substrate p-nitrophenyl-N-acetylneuraminic acid (p-NP-Neu5Ac). Using our assay, the measured kinetic parameters of the three purified pneumococcal sialidase, NanA, NanB and NanC, were obtained and were in perfect agreement with the previously published data. The major advantage of this alternative method resides in the direct measurement of the released product, allowing to readily determine of initial reaction rates and record complete hydrolysis time courses. CONCLUSION: We developed an accurate, fast and sensitive spectrophotometric method to investigate the kinetics of sialidase-catalyzed reactions. This fast, sensitive, inexpensive and accurate method could benefit the study of the kinetics and inhibition of sialidases in general.


Subject(s)
Neuraminidase/antagonists & inhibitors , Biocatalysis , Buffers , Hydrogen-Ion Concentration , Hydrolysis , Kinetics , N-Acetylneuraminic Acid/metabolism , Neuraminidase/genetics , Neuraminidase/metabolism , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Spectrophotometry, Ultraviolet , Streptococcus pneumoniae/enzymology , Substrate Specificity
4.
BMC Microbiol ; 12: 200, 2012 Sep 11.
Article in English | MEDLINE | ID: mdl-22963456

ABSTRACT

BACKGROUND: Sialic acid (N-acetylneuraminic acid; NeuNAc) is one of the most important carbohydrates for Streptococcus pneumoniae due of its role as a carbon and energy source, receptor for adhesion and invasion and molecular signal for promotion of biofilm formation, nasopharyngeal carriage and invasion of the lung. RESULTS: In this work, NeuNAc and its metabolic derivative N-acetyl mannosamine (ManNAc) were used to analyze regulatory mechanisms of the neuraminidase locus expression. Genomic and metabolic comparison to Streptococcus mitis, Streptococcus oralis, Streptococcus gordonii and Streptococcus sanguinis elucidates the metabolic association of the two amino sugars to different parts of the locus coding for the two main pneumococcal neuraminidases and confirms the substrate specificity of the respective ABC transporters. Quantitative gene expression analysis shows repression of the locus by glucose and induction of all predicted transcriptional units by ManNAc and NeuNAc, each inducing with higher efficiency the operon encoding for the transporter with higher specificity for the respective amino sugar. Cytofluorimetric analysis demonstrated enhanced surface exposure of NanA on pneumococci grown in NeuNAc and ManNAc and an activity assay allowed to quantify approximately twelve times as much neuraminidase activity on induced cells as opposed to glucose grown cells. CONCLUSIONS: The present data increase the understanding of metabolic regulation of the nanAB locus and indicate that experiments aimed at the elucidation of the relevance of neuraminidases in pneumococcal virulence should possibly not be carried out on bacteria grown in glucose containing media.


Subject(s)
Gene Expression Regulation, Bacterial , Neuraminidase/biosynthesis , Streptococcus pneumoniae/genetics , Streptococcus pneumoniae/metabolism , Gene Expression Profiling , Hexosamines/metabolism , Humans , N-Acetylneuraminic Acid/metabolism , Operon
5.
J Infect Dis ; 199(10): 1497-505, 2009 May 15.
Article in English | MEDLINE | ID: mdl-19392624

ABSTRACT

The correlation between carbohydrate availability, pneumococcal biofilm formation, nasopharyngeal colonization, and invasion of the host has been investigated. Of a series of sugars, only sialic acid (i.e., N-acetylneuraminic acid) enhanced pneumococcal biofilm formation in vitro, at concentrations similar to those of free sialic acid in human saliva. In a murine model of pneumococcal carriage, intranasal inoculation of sialic acid significantly increased pneumococcal counts in the nasopharynx and instigated translocation of pneumococci to the lungs. Competition of both sialic acid-dependent phenotypes was found to be successful when evaluated using the neuraminidase inhibitors DANA (i.e., 2,3-didehydro-2-deoxy-N-acetylneuraminic acid), zanamivir, and oseltamivir. The association between levels of free sialic acid on mucosae, pneumococcal colonization, and development of invasive disease shows how a host-derived molecule can influence a colonizing microbe and also highlights a molecular mechanism that explains the epidemiologic correlation between respiratory infections due to neuraminidase-bearing viruses and bacterial pneumonia. The data provide a new paradigm for the role of a host compound in infectious diseases and point to new treatment strategies.


Subject(s)
Biofilms/growth & development , N-Acetylneuraminic Acid/metabolism , Pneumococcal Infections/diagnosis , Streptococcus pneumoniae/physiology , Streptococcus pneumoniae/pathogenicity , Animals , DNA Primers , Gene Expression Regulation, Bacterial/drug effects , Humans , Mice , N-Acetylneuraminic Acid/analogs & derivatives , N-Acetylneuraminic Acid/analysis , N-Acetylneuraminic Acid/pharmacology , Neuraminidase/antagonists & inhibitors , Pneumococcal Infections/transmission , Saliva/chemistry , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/genetics , Zanamivir/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...